Devanshi Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Devanshi Jain has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ajit Sood
Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India
3 shared publications - Arshdeep Singh
Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India
3 shared publications - Arshia Bhardwaj
Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India
3 shared publications - Dharmatma Singh
Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India
3 shared publications - Riya Sharma
Research and Development Center, Dayanand Medical College and Hospital, Ludhiana, India
3 shared publications - Vandana Midha
Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India
3 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16
Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis
In acute severe ulcerative colitis (ASUC), early response patterns to intravenous corticosteroids (IVCS) during the first week may shape subsequent disease course. Characterizing these trajectories is crucial for guiding timely therapy and improving patient outcomes. We evaluated response patterns to IVCS in hospitalized patients with ASUC. Clinical response was categorized as complete response (CR), partial response (PR), or non-response (NR) on days 3, 5, and 7. Patients were followed up to day 90 for need for rescue therapy (RT), post-discharge escalation of therapy (EOT), and mortality. Seventy-nine patients were analyzed. By day 3, 12 (15%) achieved CR, 34 (43%) PR, and 33 (42%) NR. Among the 67 patients with PR or NR on day 3, 9 (13.4%) achieved CR by day 5 and 22 (32.8%) more by day 7. On day 7, CR, PR, and NR were observed in 42 (53%), 17 (21%), and 20 (25%) patients, respectively. Patients with CR on day 3 had a lower, but not statistically significant, likelihood of needing RT + EOT by day 90 compared to NR (29% vs. 47%; p = 0.15). However, by day 5, patients with CR or PR had significantly lower day 90 RT + EOT needs compared to NR (26% vs. 54%, p = 0.02; 23% vs. 54%, p = 0.03). By day 7, the day 90 probability of RT + EOT was higher in PR (45%) and NR (63%) versus CR (16%) (p = 0.001 and < 0.0001, respectively). Only a small proportion of patients with ASUC show CR at day 3; most are partial responders. Partial responders to IVCS at day 3 frequently achieve CR by day 5–7, and have relatively favorable short term disease course, highlighting the prognostic value of early response stratification.
- 30 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16
Open AccessPartial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis
In acute severe ulcerative colitis (ASUC), early response patterns to intravenous corticosteroids (IVCS) during the first week may shape subsequent disease course. Characterizing these trajectories is crucial for guiding timely therapy and improving patient outcomes. We evaluated response patterns to IVCS in hospitalized patients with ASUC. Clinical response was categorized as complete response (CR), partial response (PR), or non-response (NR) on days 3, 5, and 7. Patients were followed up to day 90 for need for rescue therapy (RT), post-discharge escalation of therapy (EOT), and mortality. Seventy-nine patients were analyzed. By day 3, 12 (15%) achieved CR, 34 (43%) PR, and 33 (42%) NR. Among the 67 patients with PR or NR on day 3, 9 (13.4%) achieved CR by day 5 and 22 (32.8%) more by day 7. On day 7, CR, PR, and NR were observed in 42 (53%), 17 (21%), and 20 (25%) patients, respectively. Patients with CR on day 3 had a lower, but not statistically significant, likelihood of needing RT + EOT by day 90 compared to NR (29% vs. 47%; p = 0.15). However, by day 5, patients with CR or PR had significantly lower day 90 RT + EOT needs compared to NR (26% vs. 54%, p = 0.02; 23% vs. 54%, p = 0.03). By day 7, the day 90 probability of RT + EOT was higher in PR (45%) and NR (63%) versus CR (16%) (p = 0.001 and < 0.0001, respectively). Only a small proportion of patients with ASUC show CR at day 3; most are partial responders. Partial responders to IVCS at day 3 frequently achieve CR by day 5–7, and have relatively favorable short term disease course, highlighting the prognostic value of early response stratification.
- Open Access
- 30 April 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (2) , 236-247
Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India
Background/Aims: Acute severe ulcerative colitis (ASUC) is a time-critical situation requiring urgent intervention. Limited data exist on the evolving clinical spectrum of ASUC in the era of advanced therapies. Methods: This prospective real-world observational cohort study included 145 adult patients hospitalized with ASUC between January 2020 and June 2024. ASUC was defined by the modified Truelove and Witts criteria. Demographics and disease characteristics, including disease severity, probable precipitating factors, and corticosteroid failure rates, were recorded. Results: The median age of patients was 36 years (interquartile range, 26–48.5 years) with 63 females (43.4%). Most patients had left-sided colitis (53.1%). The median disease duration was 1 year (IQR, 0.5–3 years), with 91 patients (62.7%) presenting with ASUC within the first year of diagnosis of ulcerative colitis. One-third of the patients had previous exposure to biologics and small molecules. The most commonly reported probable precipitants of ASUC were poor compliance with treatment (n = 43, 29.6%), antibiotic use (n = 35, 24.1%), high perceived stress (n = 32, 22.1%), and Clostridioides difficile infection (n = 19, 13.1%). Forty patients (27.5%) were non-responders to intravenous corticosteroids (IVCS). Twenty-nine patients (20%) received medical rescue therapy (infliximab, n = 14 [48.27%], cyclosporine A, n = 6 [20.68%], and tofacitinib, n = 9 [31.03%]). Seven patients (4.82%; 4 after non-response to IVCS and 3 after non-response to medical rescue therapy) underwent colectomy. Conclusions: In this cohort of ASUC patients, poor treatment compliance, antibiotic use, stress, and C. difficile infection were common precipitants of flare-ups. Nearly one-third of patients required medical rescue therapy, and a small proportion ultimately underwent colectomy.
- 30 April 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (2) , 236-247
Open AccessClinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India
Background/Aims: Acute severe ulcerative colitis (ASUC) is a time-critical situation requiring urgent intervention. Limited data exist on the evolving clinical spectrum of ASUC in the era of advanced therapies. Methods: This prospective real-world observational cohort study included 145 adult patients hospitalized with ASUC between January 2020 and June 2024. ASUC was defined by the modified Truelove and Witts criteria. Demographics and disease characteristics, including disease severity, probable precipitating factors, and corticosteroid failure rates, were recorded. Results: The median age of patients was 36 years (interquartile range, 26–48.5 years) with 63 females (43.4%). Most patients had left-sided colitis (53.1%). The median disease duration was 1 year (IQR, 0.5–3 years), with 91 patients (62.7%) presenting with ASUC within the first year of diagnosis of ulcerative colitis. One-third of the patients had previous exposure to biologics and small molecules. The most commonly reported probable precipitants of ASUC were poor compliance with treatment (n = 43, 29.6%), antibiotic use (n = 35, 24.1%), high perceived stress (n = 32, 22.1%), and Clostridioides difficile infection (n = 19, 13.1%). Forty patients (27.5%) were non-responders to intravenous corticosteroids (IVCS). Twenty-nine patients (20%) received medical rescue therapy (infliximab, n = 14 [48.27%], cyclosporine A, n = 6 [20.68%], and tofacitinib, n = 9 [31.03%]). Seven patients (4.82%; 4 after non-response to IVCS and 3 after non-response to medical rescue therapy) underwent colectomy. Conclusions: In this cohort of ASUC patients, poor treatment compliance, antibiotic use, stress, and C. difficile infection were common precipitants of flare-ups. Nearly one-third of patients required medical rescue therapy, and a small proportion ultimately underwent colectomy.
- Open Access
- 30 April 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (2) , 144-156
Predictive accuracy of fecal calprotectin for histologic remission in ulcerative colitis
Background/Aims: Accurate assessment of disease activity is crucial for effective management and treatment of ulcerative colitis (UC). This study evaluated the correlation between clinical, endoscopic, and histologic measures of disease activity in UC. Methods: Clinical, biochemical, endoscopic, and histologic disease activity was studied in 347 patients with UC. Agreements among various histologic classification systems, namely the Geboes Score (GS), Continuous GS, Nancy Index (NI), and Robarts Histopathology Index (RHI), were analyzed. The predictive accuracy of fecal calprotectin (FC) for endoscopic and histologic remission was assessed. Results: We demonstrate a fair to moderate correlation between clinical, endoscopic, and histologic measures of disease activity in UC. There was a robust concordance among GS, Continuous GS, NI, and RHI in distinguishing between patients in histologic remission or activity. The NI detected 75% of patients who met the remission criteria according to the RHI, whereas the RHI identified all patients in remission as defined by the NI. FC levels below 150 μg/g had >70% accuracy in predicting endoscopic remission. FC levels below 150 μg/g showed ≥80% accuracy, and FC levels below 100 μg/g demonstrated ≥ 85% accuracy in predicting histologic remission, regardless of the scoring index applied. Elevated FC levels were associated with both acute and chronic inflammatory infiltrates in biopsy samples. Conclusions: FC is a reliable predictor of histologic remission, with higher accuracy at lower thresholds. The GS, Continuous GS, NI, and RHI demonstrate comparable performance. FC could help stratify patients’ need for colonoscopy for the assessment of endoscopic and histologic remission.
- 30 April 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (2) , 144-156
Open AccessPredictive accuracy of fecal calprotectin for histologic remission in ulcerative colitis
Background/Aims: Accurate assessment of disease activity is crucial for effective management and treatment of ulcerative colitis (UC). This study evaluated the correlation between clinical, endoscopic, and histologic measures of disease activity in UC. Methods: Clinical, biochemical, endoscopic, and histologic disease activity was studied in 347 patients with UC. Agreements among various histologic classification systems, namely the Geboes Score (GS), Continuous GS, Nancy Index (NI), and Robarts Histopathology Index (RHI), were analyzed. The predictive accuracy of fecal calprotectin (FC) for endoscopic and histologic remission was assessed. Results: We demonstrate a fair to moderate correlation between clinical, endoscopic, and histologic measures of disease activity in UC. There was a robust concordance among GS, Continuous GS, NI, and RHI in distinguishing between patients in histologic remission or activity. The NI detected 75% of patients who met the remission criteria according to the RHI, whereas the RHI identified all patients in remission as defined by the NI. FC levels below 150 μg/g had >70% accuracy in predicting endoscopic remission. FC levels below 150 μg/g showed ≥80% accuracy, and FC levels below 100 μg/g demonstrated ≥ 85% accuracy in predicting histologic remission, regardless of the scoring index applied. Elevated FC levels were associated with both acute and chronic inflammatory infiltrates in biopsy samples. Conclusions: FC is a reliable predictor of histologic remission, with higher accuracy at lower thresholds. The GS, Continuous GS, NI, and RHI demonstrate comparable performance. FC could help stratify patients’ need for colonoscopy for the assessment of endoscopic and histologic remission.